Corbus Pharmaceuticals (CRBP) Corporate presentation summary

Key clinical milestones and financial position

• Major clinical readouts in 2026 include CRB-701 updates in HNSCC and cervical cancer, CRB-913 dose-finding data in obesity, and CRB-601 dose escalation data.

• $173M in cash, cash equivalents, and investments as of November 2025, with 17.6M shares outstanding (20.5M fully diluted).

Diversified pipeline and development focus

• Pipeline includes next-generation Nectin-4 ADC (CRB-701), peripherally restricted CB1R inverse agonist (CRB-913), and anti-avβ8 mAb (CRB-601).

• CRB-701 targets solid tumors with FDA Fast Track Designation for HNSCC and cervical cancer.

• CRB-913 addresses obesity and related conditions, with a 12-week dose-range study in 2026.

• CRB-601 targets TGFB in solid tumors, with dose escalation data expected.

CRB-701: Clinical profile and competitive positioning

• Demonstrates reduced toxicities and longer half-life compared to PADCEV®, enabling higher dosing and less frequent administration.

• Shows efficacy in tumors with high Nectin-4 expression, including HNSCC and cervical cancer.

• Lower levels of free MMAE and favorable safety profile versus PADCEV® and other Nectin-4 ADCs.

• Phase 1/2 data show promising ORR and DCR in HNSCC and cervical cancer, with responses across biomarker subgroups.

• Fast Track status granted for cervical cancer; registrational studies planned for 2026.